Clinical safety rating: safe
Topical ophthalmic corticosteroid used for inflammatory eye conditions. Systemic absorption from ophthalmic administration is negligible (<1%). No clinically meaningful fetal exposure occurs at standard ophthalmic doses. Safe to use for appropriate eye conditions throughout pregnancy.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators such as prostaglandins and leukotrienes.
| Metabolism | Primarily hepatic, via CYP3A4 and other enzymes; also local metabolism in ocular tissues. |
| Excretion | Renal (primarily as metabolites): ~70% after oral dose; unchanged drug: <20%. Biliary/fecal: minor. |
| Half-life | Plasma: 2-4 hours; tissue effects persist 18-36 hours. Clinically, duration of adrenal suppression may exceed plasma half-life. |
| Protein binding | 70-90%, primarily to albumin and corticosteroid-binding globulin (CBG, transcortin). |
| Volume of Distribution | 0.6-1.5 L/kg. Indicates extensive tissue distribution, including ocular tissues. |
| Bioavailability | Ophthalmic: not systemic bioavailability typically quoted; systemic absorption is low (<1%) after topical administration, though may increase with prolonged use or damaged corneal epithelium. |
| Onset of Action | Ophthalmic: within 24 hours for anti-inflammatory effect; maximal effect at 2-3 days. |
| Duration of Action | Ophthalmic: anti-inflammatory effect persists for 24-48 hours after single dose. Use TID to QID for maintenance. |
| Molecular Weight | 360.44 |
Instill 1-2 drops into the conjunctival sac of the affected eye(s) four times daily. In severe cases, dosing may be initiated with 1-2 drops every 1-2 hours and tapered upon improvement.
| Renal impairment | No dosage adjustment required for renal impairment. Systemic absorption is minimal; however, caution is advised in severe renal disease due to potential corticosteroid adverse effects. |
| Liver impairment | No specific adjustment recommended for hepatic impairment. Use with caution in severe hepatic disease due to potential for increased systemic exposure. |
| Pediatric use | Children: Instill 1 drop into the affected eye(s) every 4-6 hours. Use lowest effective dose for shortest duration. Safety and efficacy in pediatric patients have not been established for prolonged use. |
| Geriatric use | Elderly: Same dosing as adults. Monitor for increased intraocular pressure and cataract formation, as elderly patients may be more susceptible to corticosteroid-induced ocular adverse effects. |
| 1st trimester | Systemic absorption from eye drops is minimal; however, avoid high doses or prolonged use due to possible increased risk of oral clefts, though risk is low. |
| 2nd trimester | Generally considered safe; use only if clearly needed, as minimal systemic absorption is expected. |
| 3rd trimester | Safe at recommended doses; prolonged use may theoretically cause fetal adrenal suppression, but risk is low. |
Clinical note
Topical ophthalmic corticosteroid used for inflammatory eye conditions. Systemic absorption from ophthalmic administration is negligible (<1%). No clinically meaningful fetal exposure occurs at standard ophthalmic doses. Safe to use for appropriate eye conditions throughout pregnancy.
| Placental transfer | Minimal; extensive first-pass metabolism and rapid clearance limit systemic exposure. Prednisolone crosses placenta but eye drops result in negligible concentrations. |
| Breastfeeding |
■ FDA Black Box Warning
None
| Common Effects | Burning sensation Eye irritation Watery eyes Blurred vision Reduction in bone density Upset stomach Behavioral changes Mood changes Weight gain |
| Serious Effects |
Hypersensitivity to prednisolone or any componentUntreated bacterial, fungal, viral, or parasitic eye infectionsCorneal epithelial herpes simplex (dendritic keratitis)Vaccinia, varicella, or other viral infections of the cornea or conjunctiva
| Precautions | Increased intraocular pressure with prolonged use, Cataract formation with long-term use, Exacerbation of corneal infections, Systemic absorption may occur |
| Food/Dietary | No significant food interactions. No specific dietary restrictions. |
Loading safety data…
| Minimal systemic absorption leads to negligible levels in breast milk. Considered compatible with breastfeeding; apply after nursing to reduce infant exposure. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~1.3-3.3). Second and third trimesters: Risk of fetal growth restriction, adrenal suppression in neonate after prolonged use. Systemic absorption from eye drops is minimal but possible with frequent dosing. |
| Fetal Monitoring | Monitor intraocular pressure, corneal integrity. In prolonged use, assess for maternal glucose intolerance, blood pressure. Fetal ultrasound for growth if high-dose prolonged therapy. |
| Fertility Effects | No known impairment of fertility based on available data. Corticosteroids may affect menstrual cycle at high systemic doses; unlikely with ophthalmic use. |
| Clinical Pearls | Use with caution in patients with corneal epithelial defects or infections; risk of herpes simplex keratitis reactivation and fungal overgrowth. Monitor intraocular pressure with prolonged use; consider tonometry if therapy exceeds 2 weeks. Avoid in patients with known steroid-induced glaucoma or ocular hypertension. Shake suspension well before instillation. Prescribe minimum effective duration to reduce cataract risk. |
| Patient Advice | Shake the bottle well before each use to ensure the medication is evenly mixed. · Do not touch the dropper tip to your eye or any surface to avoid contamination. · Remove contact lenses before instillation and wait at least 15 minutes before reinserting. · Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after drops to reduce systemic absorption. · Do not use the drops if you have a viral or fungal eye infection unless directed by your doctor. · Report any eye pain, vision changes, or signs of infection (redness, discharge) promptly. · Do not stop therapy abruptly; follow your doctor's instructions for tapering if needed. · Store at room temperature away from light and moisture; discard 4 weeks after opening. |